Kardium Inc., a Vancouver-based medical device innovator, has raised $250 million in a heavily oversubscribed financing round to support the commercial launch of the GlobeĀ® Pulsed Field System, a breakthrough treatment for atrial fibrillation (AF).
The round was led by new investors including Janus Henderson Investors, Qatar Investment Authority (QIA), MMCAP, Piper Heartland Healthcare Capital, Eventide Asset Management, and Eckuity Capital. T. Rowe Price Associates, Inc., T. Rowe Price Investment Management, Inc., and Durable Capital Partners LPāall existing investorsāalso participated. The funding round includes an equity investment from a leading strategic investor.
āWeāre thrilled to have secured this transformational financing with a world-class syndicate of investors,ā said Kevin Chaplin, CEO of Kardium. āThis funding enables us to move ahead with the commercial launch of the Globe System by expanding our manufacturing capabilities and building a strong commercial team. Everyone at Kardium is energized by the opportunity to bring the Globe System to market and help improve the lives of millions of patients worldwide suffering from atrial fibrillation.ā
Aaron Schaechterle, Portfolio Manager at Janus Henderson Investors, added:
āThe Globe System is a disruptive innovation with exemplary clinical outcomes that has the potential to improve the lives of patients with atrial fibrillation. This is a pivotal moment in the evolution of AF treatment, as the field transitions toward pulsed field ablation, and we are proud to help support the introduction of Kardiumās groundbreaking technology to the market.ā
Clinical data from the pivotal PULSAR trial, presented at the 2025 Heart Rhythm Society annual meeting, demonstrated freedom from atrial arrhythmia at one year in 78% of paroxysmal AF patients, with 0% device-related primary safety events.
The new funding will allow Kardium to:
- Pursue regulatory approvals
- Expand manufacturing capacity
- Build a clinical and commercial team
- Advance clinical research for broader indications
At the core of the Globe System is a sophisticated 122-electrode catheter and advanced software capable of high-definition mapping, pulmonary vein isolation, and full atrial ablationāall using a single device.
About Kardium
Founded in 2007, Kardium Inc. is a privately held Canadian medical technology company developing next-generation solutions for cardiac electrophysiology. Headquartered in Vancouver, Kardium consistently ranks among British Columbia’s top employers and works closely with top cardiology advisors to deliver life-changing innovations.
